TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10202313
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 6 microm monodisperse Teflon particles labelled with 111In (control measurement)
Study: 2281671
Drug: anxiolytic drug
Normalized name: ANXIOLYTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: anxiolytic drug
Study: 26156269
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthetic administration with vibration
Study: 26156269
Drug: Injections without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injections without the use of vibration
Study: 22484576
Drug: FEC (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2)) followed by DOC (3 courses of docetaxel 100 mg/m(2))
Study: 22484576
Drug: DOC (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOC (3 courses of docetaxel 100 mg/m(2)) followed by FEC (3 courses of fluorouracil 500 mg/m(2), epirubicin 100 mg/m(2), and cyclophosphamide 500 mg/m(2))
Study: 16923097
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 microg/kg, Midazolam 0.03 mg/kg, Propofol 2.5 mg/kg (group FMP)
Study: 16923097
Drug: Fentanyl 2
Normalized name: fentanyl 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 2 microg/kg, Lignocaine 1.5 mg/kg, Propofol 2.5 mg/kg (group FLP)
Study: 12784100
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg q.d.
Study: 12784100
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg b.i.d.
Study: 12784100
Drug: Desipramine 50
Normalized name: desipramine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desipramine 50 mg b.i.d.
Study: 10864586
Drug: L‐NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (3 mg/kg priming dose + 3 mg/kg per h)
Study: 10864586
Drug: HOI superimposed
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HOI superimposed on L‐NMMA infusion
Study: 10864586
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (time control)
Study: 10864586
Drug: HOI without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HOI without L‐NMMA infusion
Study: 8875556
Drug: alpha-tocopherol acetate
Normalized name: alpha-Tocopherol acetate
DrugBank: alpha-Tocopherol acetate (DB14003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: alpha-tocopherol acetate (125 mg/g) applied twice daily for three months
Study: 8875556
Drug: difluoromethylornithine cream
Normalized name: α-difluoromethylornithine
DrugBank: Eflornithine (DB06243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: difluoromethylornithine cream applied twice daily for three months
Study: 1843365
Drug: Quassia Amarga
Normalized name: QUASSIA
DrugBank: Quassia (DB13263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quassia Amarga (alcoholic solution)
Study: 29518094
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous insulin lispro infusion (CSII)
Study: 29518094
Drug: Once-daily insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily insulin isophane
Study: 26682871
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy in the low-risk group (GH >67)
Study: 26682871
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy in the intermediate-risk group (46 ≤ GH ≤ 67)
Study: 26682871
Drug: Doublet chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doublet chemotherapy in the high-risk group (GH <46)
Study: 24456362
Drug: Doenjang (9.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doenjang (9.8 g/day)
Study: 15775733
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) 0.625 mg conjugated equine estrogens (CEE) combined with 2.5 mg medroxyprogesterone
Study: 15775733
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HRT and Simvastatin (20 mg)
Study: 16369229
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg)
Study: 10559578
Drug: budesonide‐printed polyester
Approvals — FDA: no, EMA: no, PMDA: no
Description: budesonide‐printed polyester squares in serial doses (150‐0.074 microg/cm(2))
Study: 7586263
Drug: 80-cc can
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80-cc can size
Study: 7586263
Drug: 60-cc can
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-cc can size
Study: 7586263
Drug: 40-cc can
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-cc can size
Study: 2122037
Drug: Oral branched-chain
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral branched-chain amino acids (BCAA)
Study: 204248
Drug: 0.02% solution
Normalized name: Atrovent 0.02% Solution for Inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% solution of prodigiosan administered intranasally (0.2 ml once every 4 days for 4 months)
Study: 21422866
Drug: Vaginal pH-balanced
Normalized name: Fem pH Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal pH-balanced gel (administered three times per week for 12 weeks)
Study: 21422866
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered three times per week for 12 weeks)
Study: 19363969
Drug: Three 15-minute
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 15-minute in-office bleaching treatments with 36% hydrogen peroxide followed by at-home overnight bleaching with 15% carbamide peroxide for seven days.
Study: 19363969
Drug: 40-minute in-office
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-minute in-office bleaching treatment followed by at-home overnight bleaching for seven days.
Study: 19363969
Drug: In-office treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-office treatment without at-home bleaching.
Study: 15226561
Drug: Cefpodoxime 5
Normalized name: cefpodoxime 50 MG in 5 mL Oral Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime 5 mg/kg b.i.d. for 10-14 days
Study: 15226561
Drug: Cefixime 4
Normalized name: cefixime 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefixime 4 mg/kg b.i.d. for 10-14 days
Study: 2462943
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy and RT
Study: 1276818
Drug: Medium-dose corticosteroids
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-dose corticosteroids
Study: 21948693
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise group (PEG) - 60 minutes of supervised exercise twice a week for 8 weeks
Study: 15756184
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of morphine, bupivacaine, and epinephrine
Study: 15756184
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of bupivacaine and epinephrine
Study: 15756184
Drug: Preoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative analgesic injections
Study: 15756184
Drug: Postoperative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesic injections
Study: 15756184
Drug: Preoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative treatment medication
Study: 10214482
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg intramuscular ketorolac upon surgical closure and every 6 hours for 36 hours and narcotic analgesics as needed (PRN)
Study: 10214482
Drug: Only narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only narcotic analgesics as needed
Study: 7793999
Drug: UFT (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT (400 or 600 mg/body per day)
Study: 11605931
Drug: rapacuronium (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium (1.5 mg/kg)
Study: 11605931
Drug: cis-atracurium (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: cis-atracurium (0.2 mg/kg)
Study: 27236292
Drug: Active low-level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-level laser therapy (LLLT)
Study: 30244669
Drug: Placebo low-level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo low-level laser therapy (LLLT)
Study: 19837071
Drug: Famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (40 mg, morning and evening)
Study: 19837071
Drug: Pantoprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (20 mg in the morning and placebo in the evening)
Study: 9527781
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir sulfate 400 mg
Study: 9527781
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir sulfate 800 mg
Study: 8544974
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking with nicotine levels of < 0.1 mg
Study: 8544974
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking with nicotine levels of 0.6 mg
Study: 8544974
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking with nicotine levels of 1.0 mg
Study: 8544974
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking with nicotine levels of 2.1 mg
Study: 2404478
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment leading to normalization of hemoglobin A1 value to 7.0% +/- 0.3%
Study: 2404478
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with persistent hyperglycemia (hemoglobin A1 value, 10.7% +/- 0.7%)
Study: 30646965
Drug: Gabapentin (accumulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (accumulating dose of 45 to 63 mg/kg/day, dependent on age) as add-on to morphine
Study: 30646965
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as add-on to morphine
Study: 6750532
Drug: Acyclovir therapy
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir therapy (5 to 10 mg/kg/8 hours, 60 minutes intravenous infusions, three times a day for 6 or 11 days)
Study: 3010782
Drug: Acyclovir therapy
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir therapy
Study: 31679946
Drug: Elexacaftor 200
Normalized name: Elexacaftor
DrugBank: Elexacaftor (DB15444)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Elexacaftor 200 mg orally once daily plus tezacaftor 100 mg orally once daily plus ivacaftor 150 mg orally every 12 h
Study: 17032159
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy plus treatment as usual
Study: 10946861
Drug: 17beta-estradiol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17beta-estradiol (1 mg twice daily orally)
Study: 12030918
Drug: GHRP-2 infusion
Normalized name: Interleukin-2/diptheria toxin fusion protein
DrugBank: Denileukin diftitox (DB00004)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GHRP-2 infusion
Study: 10946861
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with E2 and GHRP-2
Study: 7844011
Drug: Lead weights
Normalized name: lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lead weights (0.8 to 2.0 g) glued to the upper lid with adhesive (Combihesive* or Tesafix)
Study: 3041973
Drug: Combination homeopathic
Normalized name: Urtica urens homeopathic preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination homeopathic preparation (Gripp-Heel)
Study: 31493775
Drug: KC for
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KC for 60 min daily
Study: 31493775
Drug: KC for
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: KC for 120 min daily
Study: 26196695
Drug: Linezolid (600-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linezolid (600-mg twice daily)
Study: 23630950
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg QD for 12 weeks
Study: 23630950
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg QD for 12 weeks
Study: 20072091
Drug: Hextend (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hextend (15 mL/kg administered during surgery)
Study: 20072091
Drug: Voluven (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluven (15 mL/kg administered during surgery)
Study: 16997114
Drug: Amlexanox oral
Normalized name: amlexanox Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlexanox oral adhesive tablets applied 4 times a day for 5 days
Study: 7790244
Drug: Conventional photon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photon therapy (70 Gy/35 fractions/7 weeks)
Study: 7790244
Drug: Conventional photon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional photon therapy
Study: 2192184
Drug: Hythiol (L‐cysteine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hythiol (L‐cysteine)
Study: 393182
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cimetidine (H2 antagonist) and chlorpheniramine (H1 antagonist)
Study: 393182
Drug: Chlorpheniramine (H1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (H1 antagonist)
Study: 3259413
Drug: Cimetidine (H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (H2 antagonist)
Study: 6353233
Drug: other therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: other therapies
Study: 30215466
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron (4 mg, 5 min)
Study: 30215466
Drug: Intramuscular ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular ephedrine (25 mg, 25 min)
Study: 30215466
Drug: Ringer (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer (500 ml, 20 min)
Study: 24126180
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of autologous mononuclear stem cells
Study: 22408779
Drug: Alendronate 70
Normalized name: ALENDRONATE 70MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 70 mg weekly for 6 months
Study: 22408779
Drug: Alendronate administered
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate administered after osseointegration for 6 months
Study: 26439944
Drug: Levodopa infusion
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa infusion
Study: 15845179
Drug: Continuous thoracic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous thoracic radiation therapy (50 Gy delivered in 2.0-Gy fractions over 5 weeks)
Study: 15845179
Drug: Interdigitating split-course
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interdigitating split-course thoracic radiation therapy (50 Gy delivered in 2.5-Gy fractions over 8 weeks)
Study: 10630349
Drug: Herbal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal treatment prescribed by traditional healers
Study: 10630349
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment or acyclovir (Control)
Study: 31050715
Drug: Acetaminophen (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (1,000 mg daily)
Study: 31050715
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg potassium daily)
Study: 31050715
Drug: Empty control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empty control (no pill)
Study: 26507858
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment with budesonide induction and azathioprine maintenance
Study: 26507858
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment with open ileocaecal resection
Study: 30901867
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone
Study: 24299928
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone (Early)
Study: 24299928
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (Early)
Study: 24299928
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone (Late)
Study: 24299928
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg dexamethasone (Late)
Study: 19021129
Drug: Pre-existing knowledge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-existing knowledge of chemotherapy-associated cognitive problems
Study: 7852666
Drug: Theophylline (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (once daily slow-release, mean serum concentration 16 +/- 5 micrograms/ml)
Study: 7852666
Drug: Cromolyn (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn (2 mg administered by MDI four times daily)
Study: 7852666
Drug: Theophylline (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (once daily slow-release)
Study: 498698
Drug: Alprenolol treatment
Normalized name: alprenolol
DrugBank: Alprenolol (DB00866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol treatment (200 to 400 mg twice daily)
Study: 19527386
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral lycopene daily
Study: 8882920
Drug: Cognitive-behavioural treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural treatment (CBT)
Study: 17654408
Drug: Combined pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacological and psychological treatment
Study: 17654408
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (pharmacological and psychological)
Study: 17654408
Drug: Generalized anxiety
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized anxiety disorder treatments
Study: 29371105
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) in combination with one to two NRTIs
Study: 29371105
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitors (PI/r) in combination with one to two NRTIs
Study: 20975464
Drug: Heated lidocaine/tetracaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated lidocaine/tetracaine patch (active patch)
Study: 17942819
Drug: Intranasal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal insulin (20 IU BID)
Study: 16313838
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated hepatitis A vaccine (H2 strain)
Study: 16313838
Drug: Vaccine coverage
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine coverage
Study: 12202710
Drug: Iopamidol with
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopamidol with iodine concentration of 370 mg/mL (Group B)
Study: 12202710
Drug: Iopamidol with
Normalized name: Iopamidol
DrugBank: Iopamidol (DB08947)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iopamidol with iodine concentration of 300 mg/mL (Group A)
Study: 8670596
Drug: Aminohexane bisphosphonate
Normalized name: methylene diphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminohexane bisphosphonate 400 mg (AHBP)
Study: 8670596
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate 2 mg and dydrogesterone 5 mg (E/D)
Study: 3533562
Drug: pindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: pindolol (10 mg)
Study: 2872795
Drug: nadolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: nadolol (80 mg)
Study: 2872795
Drug: acebutolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (400 mg)
Study: 30176543
Drug: c.2990 G>T
Approvals — FDA: no, EMA: no, PMDA: no
Description: c.2990 G>T variant in SAM
Study: 27081036
Drug: CEpOP +/−
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEpOP +/− rituximab (R) with epirubicin (70 mg/m2/dose)
Study: 27081036
Drug: CHOP +/−
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP +/− rituximab (R) with doxorubicin (50 mg/m2/dose)
Study: 25352653
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine titrated to a fasting glucose level of ≤5.3 mmol/L (≤95 mg/dL)
Study: 26082625
Drug: QVA149 110/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 110/50 μg once daily